Skip to main content
Top
Published in: Diabetologia 8/2004

01-08-2004 | Article

Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat

Authors: N. L. Alderson, M. E. Chachich, N. Frizzell, P. Canning, T. O. Metz, A. S. Januszewski, N. N. Youssef, A. W. Stitt, J. W. Baynes, S. R. Thorpe

Published in: Diabetologia | Issue 8/2004

Login to get access

Abstract

Aims/hypothesis

This study was designed to determine whether inhibition of formation of AGE and advanced lipoxidation end-products (ALE) is a mechanism of action common to a diverse group of therapeutic agents that limit the progress of diabetic nephropathy. We compared the effects of the ACE inhibitor enalapril, the antioxidant vitamin E, the thiol compound lipoic acid, and the AGE/ALE inhibitor pyridoxamine on the formation of AGE/ALE and protection against nephropathy in streptozotocin diabetic rats.

Methods

Renal function and AGE/ALE formation were evaluated in rats treated with the agents listed above. Plasma was monitored monthly for triglycerides, cholesterol, creatinine and TNF-α, and 24-h urine samples were collected for measurement of albumin and total protein excretion. After 29 weeks, renal expression of mRNA for extracellular matrix proteins was measured, and AGE/ALE were quantified in skin and glomerular and tubular collagen.

Results

Diabetic animals were both hyperglycaemic and dyslipidaemic, and showed evidence of early nephropathy (albuminuria, creatinaemia). All interventions limited the progression of nephropathy, without affecting glycaemia. The order of efficacy was: pyridoxamine (650 mg·kg−1·day−1) > vitamin E (200 mg·kg−1·day−1) > lipoic acid (93 mg·kg−1·day−1) ~ enalapril (35 mg·kg−1·day−1). Pyridoxamine also significantly inhibited AGE/ALE accumulation in tissues; effects of other agents were mixed, but the degree of renoprotection was consistent with their effects on AGE/ALE formation.

Conclusions/interpretation

All interventions inhibited the progression of nephropathy at the doses studied, but the maximal benefit was achieved with pyridoxamine, which also limited dyslipidaemia and AGE/ALE formation. These experiments indicate that the more effective the renoprotection, the greater the inhibition of AGE/ALE formation. For optimal protection of renal function, it would be beneficial to select drugs whose mechanism of action includes inhibition of AGE/ALE formation.
Literature
1.
go back to reference Raj DSC, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a nephrologist’s perspective. Am J Kid Dis 35:365–380PubMed Raj DSC, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a nephrologist’s perspective. Am J Kid Dis 35:365–380PubMed
2.
go back to reference Stitt AW, Jenkins AJ, Cooper ME (2002) Advanced glycation end products and diabetic complications. Expert Opin Invest Drugs 11:1205–1223 Stitt AW, Jenkins AJ, Cooper ME (2002) Advanced glycation end products and diabetic complications. Expert Opin Invest Drugs 11:1205–1223
3.
go back to reference Dyer DG, Dunn JA, Thorpe SR (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463–2469PubMed Dyer DG, Dunn JA, Thorpe SR (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463–2469PubMed
4.
go back to reference Ceriello A (1999) Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 12:42–46PubMed Ceriello A (1999) Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 12:42–46PubMed
5.
go back to reference Nishikawa T, Edelstein D, Du XL et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404:787–790 Nishikawa T, Edelstein D, Du XL et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404:787–790
6.
go back to reference Suzuki D, Miyata T (1999) Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern Med 38:309–314PubMed Suzuki D, Miyata T (1999) Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern Med 38:309–314PubMed
7.
go back to reference Alderson NA, Chachich ME, Youssef NN et al. (2003) Pyridoxamine limits dyslipidemia, hypertension and early nephropathy in obese Zucker (fatty) rats. Kidney Int 63:2123–2133CrossRefPubMed Alderson NA, Chachich ME, Youssef NN et al. (2003) Pyridoxamine limits dyslipidemia, hypertension and early nephropathy in obese Zucker (fatty) rats. Kidney Int 63:2123–2133CrossRefPubMed
8.
9.
go back to reference Miyata T, Ueda Y, Asahi K et al. (2000) Mechanism of the inhibitory effect of OPB-9195 [(+/−)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11:1719–1725PubMed Miyata T, Ueda Y, Asahi K et al. (2000) Mechanism of the inhibitory effect of OPB-9195 [(+/−)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11:1719–1725PubMed
10.
go back to reference Degenhardt TP, Alderson NL, Arrington DD et al. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939–950CrossRefPubMed Degenhardt TP, Alderson NL, Arrington DD et al. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939–950CrossRefPubMed
11.
go back to reference Hamada Y, Nakamura J, Naruse K et al. (2000) Epalrestat, an aldose reductase inhibitor, reduces the levels of Nε-(carboxymethyl)-lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23:1539–1544PubMed Hamada Y, Nakamura J, Naruse K et al. (2000) Epalrestat, an aldose reductase inhibitor, reduces the levels of Nε-(carboxymethyl)-lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23:1539–1544PubMed
12.
go back to reference Forbes JM, Cooper ME, Thallas V et al. (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274–3282PubMed Forbes JM, Cooper ME, Thallas V et al. (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274–3282PubMed
13.
go back to reference Nangaku M, Miyata T, Sada T et al. (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14:1212–1222PubMed Nangaku M, Miyata T, Sada T et al. (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14:1212–1222PubMed
14.
go back to reference Jerums G, Panagiotopoulos S, Forbes J, Osicka T, Cooper M (2003) Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch Biochem Biophys 419:55–62CrossRefPubMed Jerums G, Panagiotopoulos S, Forbes J, Osicka T, Cooper M (2003) Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch Biochem Biophys 419:55–62CrossRefPubMed
15.
go back to reference Way KJ, Katai N, King GL (2001) Protein kinase C and the development of diabetic vascular complications. Diabet Med 18:945–959CrossRefPubMed Way KJ, Katai N, King GL (2001) Protein kinase C and the development of diabetic vascular complications. Diabet Med 18:945–959CrossRefPubMed
16.
go back to reference Frank RN (2002) Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 133:693–698CrossRefPubMed Frank RN (2002) Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 133:693–698CrossRefPubMed
17.
go back to reference Usui H, Shikata K, Matsuda M et al. (2003) HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18:265–272CrossRefPubMed Usui H, Shikata K, Matsuda M et al. (2003) HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18:265–272CrossRefPubMed
18.
go back to reference Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120PubMed Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120PubMed
19.
go back to reference Koya D, Lee IK, Ishii H, Kanoh H, King GL (1997) Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 8:426–435PubMed Koya D, Lee IK, Ishii H, Kanoh H, King GL (1997) Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 8:426–435PubMed
20.
go back to reference Craven PA, DeRubertis FR, Kagan VE, Melhem M, Studer RK (1997) Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes. J Am Soc Nephrol 8:1405–1414PubMed Craven PA, DeRubertis FR, Kagan VE, Melhem M, Studer RK (1997) Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes. J Am Soc Nephrol 8:1405–1414PubMed
21.
go back to reference Kim SS, Gallaher DD, Csallany AS (2000) Vitamin E and probucol reduce urinary lipophilic aldehydes and renal enlargement in streptozotocin-induced diabetic rats. Lipids 35:1225–1237PubMed Kim SS, Gallaher DD, Csallany AS (2000) Vitamin E and probucol reduce urinary lipophilic aldehydes and renal enlargement in streptozotocin-induced diabetic rats. Lipids 35:1225–1237PubMed
22.
go back to reference Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA (2000) Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006–1015PubMed Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA (2000) Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006–1015PubMed
23.
go back to reference Melhem MF, Craven PA, Liachenko J, DeRubertis FR (2002) Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 13:108–116PubMed Melhem MF, Craven PA, Liachenko J, DeRubertis FR (2002) Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 13:108–116PubMed
24.
go back to reference Melhem MF, Craven PA, Derubertis FR (2001) Effects of dietary supplementation of α-lipoic acid on early glomerular injury in diabetes mellitus. J Am Soc Nephrol 12:124–133PubMed Melhem MF, Craven PA, Derubertis FR (2001) Effects of dietary supplementation of α-lipoic acid on early glomerular injury in diabetes mellitus. J Am Soc Nephrol 12:124–133PubMed
25.
go back to reference Obrosova IG, Fathallah L, Liu E, Nourooz-Zadeh J (2003) Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid. Free Rad Biol Med 34:186–195CrossRefPubMed Obrosova IG, Fathallah L, Liu E, Nourooz-Zadeh J (2003) Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid. Free Rad Biol Med 34:186–195CrossRefPubMed
26.
go back to reference Packer L, Kraemer K, Rimbach G (2001) Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17:888–895CrossRefPubMed Packer L, Kraemer K, Rimbach G (2001) Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17:888–895CrossRefPubMed
27.
go back to reference Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW (2003) Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31:1413-1416PubMed Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW (2003) Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31:1413-1416PubMed
28.
go back to reference Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW (1991) Age-dependent accumulation of Nε(carboxymethyl)lysine and Nε−(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30:1205–1210PubMed Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW (1991) Age-dependent accumulation of Nε(carboxymethyl)lysine and Nε−(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30:1205–1210PubMed
29.
go back to reference Requena JR, Fu M-X, Ahmed MU et al. (1997) Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 322:317–325PubMed Requena JR, Fu M-X, Ahmed MU et al. (1997) Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 322:317–325PubMed
30.
go back to reference Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654–11660PubMed Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654–11660PubMed
31.
go back to reference Kreisberg JI, Karnovsky MJ (1983) Glomerular cells in culture. Kidney Int 23:439–447PubMed Kreisberg JI, Karnovsky MJ (1983) Glomerular cells in culture. Kidney Int 23:439–447PubMed
32.
go back to reference Abrass CK, Spicer D, Raugi GK (1994) Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int 46:613–620PubMed Abrass CK, Spicer D, Raugi GK (1994) Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int 46:613–620PubMed
33.
go back to reference Peterson GL (1979) Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal Biochem 100:201–220PubMed Peterson GL (1979) Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal Biochem 100:201–220PubMed
34.
go back to reference Requena JR, Price DL, Thorpe SR, Baynes JW (1999) Measurement of pentosidine in biological samples. In: Barnett Y, Barnett CR (eds) Methods in molecular medicine, vol 38: Aging, methods and protocols. Humana Press, N.J., pp 209–217 Requena JR, Price DL, Thorpe SR, Baynes JW (1999) Measurement of pentosidine in biological samples. In: Barnett Y, Barnett CR (eds) Methods in molecular medicine, vol 38: Aging, methods and protocols. Humana Press, N.J., pp 209–217
35.
go back to reference Simpson DA, Murphy GM, Bhaduri T, Gardiner TA, Archer DB, Stitt AW (1999) Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem Biophys Res Commun 262:333–340CrossRefPubMed Simpson DA, Murphy GM, Bhaduri T, Gardiner TA, Archer DB, Stitt AW (1999) Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem Biophys Res Commun 262:333–340CrossRefPubMed
36.
go back to reference Simpson DA, Feeney S, Boyle C, Stitt AW (2000) Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR. Mol Vis 6:178–183PubMed Simpson DA, Feeney S, Boyle C, Stitt AW (2000) Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR. Mol Vis 6:178–183PubMed
37.
go back to reference Stitt A, Gardiner TA, Alderson NL et al. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–2832PubMed Stitt A, Gardiner TA, Alderson NL et al. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–2832PubMed
38.
go back to reference Thorpe SR, Alderson NL, Chachich ME et al, (2002) Role of dyslipidemia and AGE/ALE formation in the progression of nephropathy and retinopathy in STZ-diabetic rats. Excerpta Med 1245:169–173CrossRef Thorpe SR, Alderson NL, Chachich ME et al, (2002) Role of dyslipidemia and AGE/ALE formation in the progression of nephropathy and retinopathy in STZ-diabetic rats. Excerpta Med 1245:169–173CrossRef
39.
go back to reference Mogyorosi A, Kapoor A, Isono M, Kapoor S, Sharma K, Ziyadeh FN (2000) Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy. Nephron 86:234–235CrossRefPubMed Mogyorosi A, Kapoor A, Isono M, Kapoor S, Sharma K, Ziyadeh FN (2000) Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy. Nephron 86:234–235CrossRefPubMed
40.
go back to reference Ziyadeh FN, Hoffman BB, Han DC et al. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020CrossRefPubMed Ziyadeh FN, Hoffman BB, Han DC et al. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020CrossRefPubMed
41.
go back to reference Miyata T, Ueda Y, Horie K et al. (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53:416–422CrossRefPubMed Miyata T, Ueda Y, Horie K et al. (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53:416–422CrossRefPubMed
42.
go back to reference Fujita A, Ueda Y, Suzuki D, Miyata T, Sakai H, Saito A (2002) Renal proximal tubular metabolism of protein-linked pentosidine, an advanced glycation end product. Nephron 91:688–694CrossRefPubMed Fujita A, Ueda Y, Suzuki D, Miyata T, Sakai H, Saito A (2002) Renal proximal tubular metabolism of protein-linked pentosidine, an advanced glycation end product. Nephron 91:688–694CrossRefPubMed
43.
go back to reference Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW (2003) Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31:1413–1416PubMed Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW (2003) Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31:1413–1416PubMed
Metadata
Title
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat
Authors
N. L. Alderson
M. E. Chachich
N. Frizzell
P. Canning
T. O. Metz
A. S. Januszewski
N. N. Youssef
A. W. Stitt
J. W. Baynes
S. R. Thorpe
Publication date
01-08-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1474-8

Other articles of this Issue 8/2004

Diabetologia 8/2004 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.